Merck & Co., Inc. (NYSE:MRK)

How Biotech and Big Pharma Have Upside Heading Into Earnings

Biotech and many of the so-called Big Pharma have been duds in 2019. Despite many FDA approvals and some powerful mergers and royalty deals, the political pressure around drug pricing ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Abbott Labs, CSX, IBM, Netflix, Occidental, Whiting, Amgen, Gilead, Merck, Pfizer and More

Stocks were indicated to open marginally higher on Thursday as the world appears to have better hopes for a Brexit framework out of Europe. Investors are having to grapple with ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

FDA Accepts for Review the Newest Treatment for C Diff

Merck & Co. Inc. (NYSE: MRK) has just announced that the U.S. Food and Drug Administration (FDA) accepted a couple New Drug Applications (NDAs) for review. Specifically, the FDA accepted ...
Read Full Story »

Why Dividend-Paying Large-Cap Pharmaceuticals Could Shine in Q4

With the final quarter of 2019 beginning next Tuesday, many investors are taking a long hard look at their portfolios and trying to make some adjustments. While the end of ...
Read Full Story »

Short Sellers Grow More Selective in Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

4 Conservative Merrill Lynch US 1 Stock Picks That Pay Reliable Dividends

You can sense that the market is getting nervous. Technicians are noting the failure to break out to new highs, in addition to the fact that we are in the ...
Read Full Story »

Will This Ebola Vaccine Be the Next Big Thing?

NewLink Genetics Corp. (NASDAQ: NLNK) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) has accepted Merck & Co.’s (NYSE: MRK) Biologics License ...
Read Full Story »

As ESG Investing Expands, the Theme’s Top Stocks Come Into Focus

With all the talk of trade war, recessions, inverted yield curves and negative interest rates in August and the start of September, many investors have every right to feel duped. ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Friday’s Top Analyst Upgrades and Downgrades: Walmart, Nvidia, Amgen, Applied Materials, Alibaba, Intel, Merck and More

This has been a rough week for the broad markets, with the S&P 500 and Dow Jones industrial average each down about 3% on last look. What’s shocking is that ...
Read Full Story »

Dividend Investors Have Reasons to Look to Big Biotech Over Big Pharma Ahead

Over the past three decades, the unlimited investing potential of biotechnology was all about growth. Companies could grow from nothing to see untold billions of dollars selling cures and treatments ...
Read Full Story »

Major Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Arconic, Boston Beer, Disney, Dunkin’, DuPont, GreenSky, IFF, Merck and More

After a big sell-off on Monday and a partial recovery on Tuesday, the markets were indicated to open lower on Wednesday as bond yields continue to slide in the wake ...
Read Full Story »